Search

Displaying results 7271 - 7280 of 10000 in total
  1. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    , and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis). … Growth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics

  2. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia).

  3. Drug

    Tesofensine

    go.drugbank.com/drugs/DB06156
    Investigational

  4. Drug

    Lexaptepid pegol

    go.drugbank.com/drugs/DB12578
    Investigational

    Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.

  5. Drug

    Dopexamine

    go.drugbank.com/drugs/DB12313
    ApprovedWithdrawn

    Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.

  6. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    -1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in

  7. Drug

    Ditazole

    go.drugbank.com/drugs/DB08994
    ApprovedWithdrawn

    Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.

  8. Drug

    Mepartricin

    go.drugbank.com/drugs/DB13633
    Investigational

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  9. Drug

    Razuprotafib

    go.drugbank.com/drugs/DB16353
    Investigational

    [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.

  10. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular deg...